# Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

> **NCT00575367** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 37 (actual)

## Conditions studied

- Bacterial Infections
- Eye Infections

## Interventions

- **DRUG:** AzaSite (azithromycin ophthalmic solution)
- **DRUG:** Vigamox (moxifloxacin hydrochloride ophthalmic solution)

## Key facts

- **NCT ID:** NCT00575367
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-10
- **Final completion:** —
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2011-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00575367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00575367, "Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00575367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*